2017
DOI: 10.1007/978-94-024-1057-0_16
|View full text |Cite
|
Sign up to set email alerts
|

Aquaporin-Targeted Therapeutics: State-of-the-Field

Abstract: Drugs targeting aquaporins have broad potential clinical applications, including cancer, obesity, edema, glaucoma, skin diseases and others. The astrocyte water channel aquaporin-4 is a particularly compelling target because of its role of brain water movement, neuroexcitation and glia scarring, and because it is the target of pathogenic autoantibodies in the neuroinflammatory demyelinating disease neuromyelitis optica. There has been considerable interest in the identification of small molecule inhibitors of … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

0
61
0
4

Year Published

2019
2019
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 62 publications
(67 citation statements)
references
References 48 publications
0
61
0
4
Order By: Relevance
“…Therefore, a s t r o c y t i c A Q P -4 s e e m s t o r e p r e s e n t a p o s s i b l e pharmacological candidate to be targeted in AD at its earliest stage, before abnormal protein accumulation and neurodegeneration occur. So far, some molecules have been tested for activity to AQP-4, but none in in vitro or in vivo models of AD (Lan et al, 2016;Tradtrantip et al, 2017). Some phytocompounds with antioxidant properties have shown to be active on AQP-4.…”
Section: Pharmacological Tools Targeting Aqp-4mentioning
confidence: 99%
“…Therefore, a s t r o c y t i c A Q P -4 s e e m s t o r e p r e s e n t a p o s s i b l e pharmacological candidate to be targeted in AD at its earliest stage, before abnormal protein accumulation and neurodegeneration occur. So far, some molecules have been tested for activity to AQP-4, but none in in vitro or in vivo models of AD (Lan et al, 2016;Tradtrantip et al, 2017). Some phytocompounds with antioxidant properties have shown to be active on AQP-4.…”
Section: Pharmacological Tools Targeting Aqp-4mentioning
confidence: 99%
“…AQP4 expression and activity in various neurological disorders has been examined, and several intriguing discoveries have been made. In cerebral edema and ischemia, AQP4 expression is increased [15,16], and inhibition of AQP4 activity, either by knockout or pretreatment with an inhibitor has been shown to cause a reduction in edema size and formation [7,[17][18][19]. However, in vasogenic edema the loss of AQP4 activity actually aggravates the condition, due to the loss of ability to remove excess water from the brain tissue [2,5,16].…”
Section: Introductionmentioning
confidence: 99%
“…Finally, AQP4 has been shown to have many roles in Alzheimer's disease, including possibly mediating the clearance of amyloid-β [36][37][38][39], and AQP4 deficiency leads to impaired learning and memory via disruption of both the glutamate transport pathway and K + ion homeostasis [40][41][42][43]. With the increase in interest in AQP4 as a potential therapeutic target [1,5,16,19], and the implications AQP4 activity has on many neurological disorders [7,14,[16][17][18][21][22][23]25,[30][31][32][33][34]42,43], it is important to have a clear understanding of the myriad of ways in which AQP4 is known to be regulated.…”
Section: Introductionmentioning
confidence: 99%
“…Vol. 25, N2, 2019 стимуляцию регуляторных белков системы комплемента, таких как CD59-ингибитор мембраноатакующего комплекса [3,107].…”
Section: аквапоринunclassified